References
Park BJ, Wannemuehler KA, Marston BA, et al.: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525–530.
Lawn SD, Harries AD, Anglaret X, et al.: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897–1908.
Bicanic T, Meintjes G, Wood R, et al.: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76–80.
Chang LW, Phipps WT, Kennedy GE, Rutherford GW: Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005, (3):CD004773.
Apisarnthanarak A, Mundy LM: The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J Acquir Immune Defic Syndr 2008, 47:644–645.
Disclosure
No potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chiller, T.M. Fluconazole Therapy for Cryptococcal Meningitis: Are Options Available Where It Is Needed Most—Africa?. Curr Fungal Infect Rep 4, 197–199 (2010). https://doi.org/10.1007/s12281-010-0036-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12281-010-0036-4